Anna‐Sofia Kiveliö
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna‐Sofia Kiveliö has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Bianca M. Carrara
Department of Obstetrics University Hospital Zürich (USZ) Zürich 8091 Switzerland
1 shared publication- Chafik Ghayor
Center of Dental Medicine, Oral Biotechnology & Bioengineering, University of Zurich, 8032 Zurich, Switzerland
1 shared publication Christopher Millan
Department of Urology University Hospital Zürich (USZ) Zürich 8091 Switzerland
1 shared publication- Martin Ehrbar
Department of Obstetrics, University and University Hospital of Zurich, Zurich, Switzerland
1 shared publication - Nicole Ochsenbein-Kölble
University Hospital Zürich
1 shared publication - Philipp S. Lienemann
Department of Obstetrics, University Hospital Zürich, Zürich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 10 February 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (10) , e2300843
Undifferentiated Human Amniotic Fluid Progenitor Cells Promote Bone Regeneration in Vivo
The treatment of large bone defects requires bone tissue substitutes. However, the lack of accessible autologous bone, especially in newborns with spina bifida or cleft palate conditions, severely limits therapeutic options involving bone grafts. Here, an engineering approach to reconstruct bone is presented by combining human amniocentesis‐derived amniotic fluid progenitor cells (hAFCs) and a biomimetic, injectable, and fully synthetic poly(ethylene glycol) hydrogel that is crosslinked enzymatically by transglutaminase FXIII (TG‐PEG). hAFCs are isolated by their colony‐forming capacity, expanded in vitro, and undergo osteogenic, chondrogenic, or adipogenic differentiation under appropriate stimulation. When encapsulated in TG‐PEG hydrogels, hAFCs rapidly deposit endogenous extracellular matrix (ECM) in vitro. hAFC‐laden TG‐PEG hydrogels containing low concentrations of bone morphogenetic protein (BMP‐2) promote formation of ectopic bone organoids in vivo in a murine model without requiring prior in vitro differentiation. Strikingly, hAFC‐induced constructs form as much bone in this model as adult bone marrow‐derived stromal cells (hBMSCs), and significantly more than adipose‐derived stromal cells (hASCs). Utilization of autologous hAFCs embedded in TG‐PEG hydrogels presents a promising therapeutic strategy for bone replacement, particularly in fetuses and newborns where limited stem cell availability can be overcome through minimally invasive harvest of amniotic fluid.
- 10 February 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (10) , e2300843
Open AccessUndifferentiated Human Amniotic Fluid Progenitor Cells Promote Bone Regeneration in Vivo
The treatment of large bone defects requires bone tissue substitutes. However, the lack of accessible autologous bone, especially in newborns with spina bifida or cleft palate conditions, severely limits therapeutic options involving bone grafts. Here, an engineering approach to reconstruct bone is presented by combining human amniocentesis‐derived amniotic fluid progenitor cells (hAFCs) and a biomimetic, injectable, and fully synthetic poly(ethylene glycol) hydrogel that is crosslinked enzymatically by transglutaminase FXIII (TG‐PEG). hAFCs are isolated by their colony‐forming capacity, expanded in vitro, and undergo osteogenic, chondrogenic, or adipogenic differentiation under appropriate stimulation. When encapsulated in TG‐PEG hydrogels, hAFCs rapidly deposit endogenous extracellular matrix (ECM) in vitro. hAFC‐laden TG‐PEG hydrogels containing low concentrations of bone morphogenetic protein (BMP‐2) promote formation of ectopic bone organoids in vivo in a murine model without requiring prior in vitro differentiation. Strikingly, hAFC‐induced constructs form as much bone in this model as adult bone marrow‐derived stromal cells (hBMSCs), and significantly more than adipose‐derived stromal cells (hASCs). Utilization of autologous hAFCs embedded in TG‐PEG hydrogels presents a promising therapeutic strategy for bone replacement, particularly in fetuses and newborns where limited stem cell availability can be overcome through minimally invasive harvest of amniotic fluid.